Table 3.
Cox regression examination investigating the impact of clinicopathological variables on patients’ disease-free survival.
| Variables | Univariable Cox regression | Multivariable Cox regression | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age | 0.990 (0.968-1.012) | 0.359 | ||
| Gender (male) | 1.067 (0.589-1.934) | 0.831 | ||
| Tumor diameter | 2.1647 (1.848-2.495) | <0.001 | 2.214 (1.859-2.637) | <0.001 |
| MWA power (High) | 0.670 (0.423-1.062) | 0.088 | 0.500 (0.309-0.810) | 0.005 |
| Complication | 1.129 (0.730-1.746) | 0.585 | ||
| Tumor differentiation (Poor) | 6.811 (4.295-10.802) | <0.001 | 3.604 (2.201-5.901) | <0.001 |
| Gene mutation | ||||
| No mutations | ref | |||
| EGFR mutations | 0.112 (0.041-0.306) | <0.001 | 0.144 (0.052-0.395) | <0.001 |
| KRAS mutations | 0.754 (0.277-2.055) | 0.581 | 0.554 (0.202-1.521) | 0.252 |
| Neutrophil | 1.325 (1.167-1.505) | <0.001 | ||
| Lymphocyte | 0.669 (0.486-0.920) | 0.014 | ||
| Monocyte | 1.491 (0.344-6.463) | 0.593 | ||
| Platelet | 1.002 (0.999-1.005) | 0.283 | ||
| SIRI (High) | 2.878 (1.941-4.266) | <0.001 | 2.391 (1.573-3.635) | <0.001 |
MWA, microwave ablation, EGFR, Epidermal Growth Factor Receptor, KRAS, Kirstenratsarcomaviraloncogenehomolog, SIRI, the ratio of monocyte multiply neutrophil to lymphocyte.